FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Capital One Closes $350MM Senior Credit Facility for Covis Pharma

December 13, 2018, 07:15 AM
Filed Under: Pharmaceuticals

Capital One announced  that it served as administrative agent and lead arranger for a $350 million senior credit facility for Covis Pharma B.V. (Covis). The facility consists of a $25 million revolver and a $325 million term loan that Covis used to acquire the worldwide rights for medicines Alvesco, Omnaris, and Zetonna.

“This is an exciting milestone for Covis, as we continue to execute on our strategy of building a global respiratory and allergy franchise,” said Michael Porter, Covis Pharma’s CEO. “Thanks to their track record and expertise in the pharmaceutical industry, Capital One was able to provide us with the required certainty of execution to help complete this transformational transaction," said Alexander Mironov, Covis’ EVP of Business Development and M&A.

“Due to our knowledge of the space and the working relationship that we have developed over time with the Covis management team, we were able to exceed the company’s expectations in a relatively compressed time frame,” said Jason Cohen, Managing Director, Capital One Healthcare.

Founded in 2011 by Cerberus Capital and Management, Covis Pharma is a specialty pharmaceutical company that focuses on acquiring high-quality, established branded pharmaceuticals and improving performance through optimizing positioning and supply chains supported by targeted product development initiatives. Covis is based in Zug Switzerland. Additional information can be found at


Week's News

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.